Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as MOR210, MOR044254, WBP2191
TJ210001 · 1 trial · 3 indications
The CTCAE criteria will be used to assess adverse events on this trial.
Based on DLT Definitions
| Arm | Type | Description |
|---|---|---|
| Dose Level 1 | EXPERIMENTAL | 1mg/kg Q1W |
| Dose Level 2 | EXPERIMENTAL | 3 mg/kg Q1W |
| Dose Level 3 | EXPERIMENTAL | 10mg/kg Q1W |
| Dose Level 4 | EXPERIMENTAL | 15 mg/kg Q1W |
| Name | Type | Description |
|---|---|---|
| TJ210001 | DRUG | human anti-C5aR monoclonal antibody |
Inclusion Criteria: 1. Males or females, of any race, age ≥ 18 years; 2. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1; 3. Willingness and ability to consent for self to participate in study and the ability to comply with scheduled visits, treatment plan, laboratory tests, and ot...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 3 | PHASE2 | Pembrolizumab, Gardasil 9 |
| Incyte Corporation | INCY | 1 | PHASE2 | Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115 |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | Aldesleukin |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
TJ210001 is an investigational small molecule being studied for the treatment of relapsed or refractory advanced solid tumors, including metastatic and advanced cancer. It is being developed by NovaBridge Biosciences and has been evaluated in a Phase 1 clinical trial in adult patients with these tumor types.
TJ210001 is being developed by NovaBridge Biosciences, which trades under the ticker NBP. The company sponsored the Phase 1 study of the drug in patients with relapsed or refractory advanced solid tumors conducted in the United States.
TJ210001 is in Phase 1 clinical development. It is an investigational agent and has not been approved by the FDA. The single Phase 1 trial evaluating TJ210001 in relapsed or refractory advanced solid tumors has been completed, and no trials are currently active.
TJ210001 was evaluated in the Phase 1 trial NCT04678921, titled Study of TJ210001 Administered in Subjects With Relapsed or Refractory Advanced Solid Tumors. The trial enrolled 16 adults aged 18 years and older of all sexes in the United States and has been completed.
The Phase 1 trial NCT04678921 was a controlled study of TJ210001 in 16 adult patients with relapsed or refractory advanced solid tumors. It was not randomized and not double blinded, and it enrolled patients aged 18 years and older of all sexes in the United States.